Analogue–based Drug Discovery II

Born out of a project of the IUPAC′s committee on Medicinal Chemistry and Drug Development, this reference addresses past and current strategies for successful drug analog development, extending the previously published volume by ten new analog classes and eight case studies. Like its precursor, this volume also contains a general section discussing universally applicable strategies for analog discovery and development. Spanning a wide range of therapeutic fields and chemical classes, the two volumes constitute the first systematic approach to drug analog development.
Of interest to virtually every researcher working in drug discovery and pharmaceutical chemistry.


Spis treści:
GENERAL ASPECTS
Optimizing Therapy by Analogues
Analogues and Standalone Drugs
Molecular Modeling in Analogue–based Drug Discovery
The Impact of Natural Products upon Modern Drug Discovery
Monoterpenoid Indole Alkaloids
Paclitaxel analogue
Issues for Patenting of Analogues
ANALOGUE CLASSES
Beta2 agonists
M3 muscarinic antagonists
SSRIs
Progestogens
DPP–IV inhibitors
PDE5 inhibitors
CB1 antagonists
Serotonin and norepinephrine reuptake inhibitors
CASE STUDIES
Eplerenone
Lapatinib
Dasatinib
Conazoles
Clevudine
Rasagiline
Liraglutide
Ramelteon


Nota biograficzna:
Janos Fischer is research laboratory head at Richter Ltd. (Budapest, Hungary). He received his education in Hungary with B.Sc. and P.h. D. degrees in organic chemistry at the Eotvos University of Budapest with Professor A. Kucsman. Between 1976–78 he was a Humboldt fellow at the University of Bonn (Germany). At Richter Ltd. he participated in the research and development of leading cardiovascular drugs in Hungary. His main interest now is analog–based drug discovery. He is author of some 100 patents and scientific publications and an elected member of the Chemistry and Human Health Div ision of IUPAC.
Robin Ganellin studied Chemistry at London University, receiving a PhD in 1958 under Professor Michael Dewar, and was a Research Associate at MIT with Arthur Cope in 1960. He then joined Smith Kline & French Laboratories in the UK and was one of the co–inventors of the revolutionary drug cimetidine (also known as Tagamet). In 1986 he was made a Fellow of the Royal Society and appointed to the SK&F Chair of Medicinal Chemistry at University College London, where he is now Emeritus Professor of Medicinal Chemistry. Professor Ganellin is co–inventor on over 160 patents and has authored 250 scientific publications. He was President of the Medicinal Chemistry Section of IUPAC and is currently Chairman of the IUPAC committee on Medicinal Chemistry and Drug Development.